Navigation Links
Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Date:2/24/2009

PARIS, January 24 /PRNewswire/ -- The European Commission has granted marketing authorisation for Servier's Valdoxan(R) /Thymanax(R) (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.

"There is still great scope for improved therapies to treat the devastating effects of depression," said Professor Goodwin from Warneford Hospital, Oxford, United Kingdom. "Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed."

Valdoxan, one 25 mg tablet taken at bedtime, offers new hope for the 33 million people in Europe suffering from major depressive episode. Valdoxan's powerful antidepressant efficacy combined with its good safety and tolerability profile is a result of its unique receptor profile. Valdoxan is the first antidepressant with melatonin receptor (MT1) and (MT2) agonist properties and 5-hydroxytryptamine (serotonin) receptor 2C (5-HT2C) antagonist properties. This unique receptor profile of Valdoxan allows for the first time the restoration of the circadian rhythms of depressed patients.(1)

Valdoxan: significant antidepressant efficacy from the start to the end of treatment

The European approval of Valdoxan is based on both short and long-term results from a large, comprehensive, international development programme including almost 6,000 adult patients with depression. The results demonstrate the superior efficacy of Valdoxan as compared with placebo, selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitor (SNRI) treatments and also show that:

    - Valdoxan has proven efficacy whatever the intensity of symptoms, in
      moderately and severely depressed adult patients 
'/>"/>
SOURCE Servier
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
3. BioLife Solutions Granted European Biopreservation Patent
4. ScinoPharm Granted US Patent for Novel Crystal Forms
5. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
6. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
7. Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Biopure Granted Additional 180 Day Compliance Period by NASDAQ
10. Skinvisible Patent Granted in Australia
11. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... PfuTurbo and Taq DNA Polymerases ,,,, pfuturbo ... PCR amplification , , Holly Hogrefe ... In this update, we compare the PCR performances ... DNA polymerase. ,PCR product yields were higher ...
... mutagenesis in less than one day , ... 28-base insertion was introduced into a plasmid vector ... created three unique restriction enzyme digestion sites. Plasmid ... transformed clones were digested with,all 3 restriction enzymes, ...
... Studying Signal Transduction,Pathways ,,,,, Obtaining the best ... ,in vivo reporting systems , Tim Sanchez ... Zheng ,Stratagene , Stratagenes PathDetect ... are used to study,activation of specific signaling pathways ...
Cached Biology Technology:PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 2PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 3PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 4Efficiently Insert Unique Restriction Sites into Plasmid Vectors 2Efficiently Insert Unique Restriction Sites into Plasmid Vectors 3Optimizing Transfection Conditions for Studying Signal Transduction Pathways 2Optimizing Transfection Conditions for Studying Signal Transduction Pathways 3Optimizing Transfection Conditions for Studying Signal Transduction Pathways 4Optimizing Transfection Conditions for Studying Signal Transduction Pathways 5Optimizing Transfection Conditions for Studying Signal Transduction Pathways 6Optimizing Transfection Conditions for Studying Signal Transduction Pathways 7
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
(Date:7/9/2014)... fever but often can be defeated with antibiotics and ... beat. Now, scientists have built a new weapon against such ... the journal ACS Applied Materials & Interfaces , their ... of them than medicine alone. , David Leong, Jianping Xie ... wait, undetectable in the human body or in places that ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Bee foraging chronically impaired by pesticide exposure: Study 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Adoptive cell transfer (ACT) therapy is used to treat patients ... of the patient's cancer cells, and some of their immune ... of the cancer cells that stimulate the T cells to ... get expanded and re-infused into the patient to mount an ...
... pandemic influenza, a new study reports for the first time ... from poultry to humans. The research appears in the ... available online. , Crossing the species barrier is an important ... potential. Previous studies have focused on the ability of highly ...
... many scientists thought, genetically modified (GM) corn has not ... , After analyzing tens of thousands of seeds from ... Mexico and the United States found no evidence of ... the researchers, said Allison Snow, a professor of evolution, ...
Cached Biology News:First Whole Genome Map of Genetic Variability in Parkinson’s Disease 2Genetically modified maize not found in southern Mexico 2
... ,Yeast extract, 5 ,Sodium chloride, 10 ... citrate, 0.5 ,IPTG, 0.03 ,-Gal ... chromogenic substrate for -galactosidase. The enzymatic ... a black insoluble precipitate. Lac+ colonies ...
... Polyclonal Antibody Epitope: aa 16-25 of ... Recommended Storage: Store vial at -20 ... use. For extended storage aliquot contents and freeze at -20 ... Family: Other Sub-Family: ...
S-100 alpha/beta chain (8B10)...
... Acetate: CoA ligase (AMP forming), Acetate ... on protein content. Physical form: ... sucrose and reduced glutathione Preparation ... mol of S-acetyl coenzyme A from acetate, ...
Biology Products: